HIGH DOSAGES OF MEPROBAMATE IN CHRONIC SCHIZOPHRENIA
Abstract
1. Meprobamate in high dosage seems to be of value in the treatment of some chronic schizophrenic patients. If it is, it will exert its clinical effects in a relatively short time.
2. High dosage meprobamate seems efficacious in the facilitation of abreactive recall, even when the drug alone is not sufficient to bring about a clinical change.
3. The absence of side-effects other than transient somnolence makes meprobamate a relatively easy drug to use in a controlled inpatient setting.
4. Further studies seem indicated to evaluate adequately large dosage meprobamate therapy in schizophrenia.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
